Ho Kyung Seo - Concepedia

Author

Ho Kyung Seo

National Cancer Center ORCID

Also Known As

H K Seo, H. Seo, H.K. Seo, HO KYUNG SEO, Ho K. Seo, Ho Kyung Seo, Ho Seo, HoKyung Seo, Hokyung Seo, Ho Kyung Seo

220

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

National Cancer Center Wonkwang University National Cancer Center University of Tsukuba The University of Texas MD Anderson Cancer Center

About

Ho Kyung Seo is an author at National Cancer Center specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	1.2K
2	Health Sciences	3	3	156
3	Engineering	1	1	16
4	Natural Sciences	1	1	11
5	Biomedical Engineering	1	1	16

Ho Kyung Seo

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, The Lancet Oncology UrologySurgical OncologyGenitourinary CancerMedicinePembrolizumab Monotherapy	2021	513
Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). Arjun Vasant Balar, Girish S. Kulkarni, Edward Uchio, Journal of Clinical Oncology UrologyPhase Ii TrialGenitourinary CancerRecurrent NmibcKeynote 057	2019	113
Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer Kang Su Cho, Ho Kyung Seo, Jae Young Joung, The Journal of Urology	2009	106
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial Andrea Necchi, M. Roumiguié, Ashish M. Kamat, The Lancet Oncology UrologySurgical OncologyOncologyGenitourinary CancerPembrolizumab Monotherapy	2024	73
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, Annals of Oncology Metastatic Urothelial CancerUrologyGenitourinary CancerSelect Fgfr AlterationsMedicine	2023	69
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer James W.F. Catto, Ben Tran, Morgan Rouprêt, Annals of Oncology	2023	67
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry Sung Han Kim, Weon Seo Park, Eun Young Park, PLoS ONE	2017	61
Pretreatment assessment of tumor enhancement on contrast‐enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy Kyung Seok Han, Dae Chul Jung, Hyuck Jae Choi, Cancer	2010	57
The outcome with ureteric stents for managing non‐urological malignant ureteric obstruction In Gab Jeong, Kyung Seok Han, Jae Young Joung, British Journal of Urology	2007	55
Intravesical Instillation of c-MYC Inhibitor KSI-3716 Suppresses Orthotopic Bladder Tumor Growth Kyung‐Chae Jeong, Kyung‐Tae Kim, Hye-Hyun Seo, The Journal of Urology	2013	54

Page 1